Join Clinical Trials in Missouri for Alzheimers Disease

All Categories Most Often Searched » Alzheimers Disease » Missouri

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812)
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified May 2012
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Condition: Alzheimer's Disease
Interventions: Drug: MABT5102A; Drug: MABT5102A; Drug: placebo; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Alzheimer's Disease Neuroimaging Initiative 2

Conditions: Mild Cognitive Impairment (MCI); Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified May 2012
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Other: Placebo
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified May 2012
Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified February 2012
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: Donepezil; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Condition: Alzheimer Disease
Intervention: Drug: Bapineuzumab 0.5 mg/kg
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

Condition: Alzheimer Disease
Intervention: Drug: ACC-001+ QS21
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified April 2012
Dominantly Inherited Alzheimer Network (DIAN)

Condition: Alzheimer's Disease
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Institute on Aging (NIA)
Recruiting - verified October 2011
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: bapineuzumab; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012